Document And Entity Information
Document And Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2019 | Mar. 27, 2020 | Jun. 28, 2019 | |
Document Information [Line Items] | |||
Entity Registrant Name | Genprex, Inc. | ||
Entity Central Index Key | 0001595248 | ||
Trading Symbol | gnpx | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Emerging Growth Company | true | ||
Entity Ex Transition Period | true | ||
Entity Small Business | true | ||
Entity Interactive Data Current | Yes | ||
Entity Common Stock, Shares Outstanding (in shares) | 32,849,841 | ||
Entity Public Float | $ 30.4 | ||
Entity Shell Company | false | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2019 | ||
Document Fiscal Year Focus | 2019 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Balance Sheets
Balance Sheets - USD ($) | Dec. 31, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash | $ 2,002,492 | $ 8,600,918 |
Accounts receivable | 655 | 9,297 |
Prepaid expenses and other | 171,716 | 236,851 |
Supplies | 801,780 | 0 |
Total current assets | 2,976,643 | 8,847,066 |
Property and equipment, net | 44,654 | 24,354 |
Other assets: | ||
Security deposits | 21,732 | 18,085 |
Intellectual property, net | 491,200 | 379,451 |
Total other assets | 512,932 | 397,536 |
Total assets | 3,534,229 | 9,268,956 |
Current liabilities: | ||
Accounts payable and accrued expenses | 436,258 | 295,069 |
Other current liabilities | 74,426 | 92,752 |
Total current liabilities | 510,684 | 387,821 |
Investment unit | 0 | 0 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Common stock $0.001 par value: 200,000,000 shares authorized; 19,263,841 and 15,239,148 shares issued and outstanding, respectively | 19,264 | 15,240 |
Additional paid-in capital | 43,483,740 | 38,690,586 |
Accumulated deficit | (40,479,459) | (29,824,691) |
Total stockholders' equity | 3,023,545 | 8,881,135 |
Total liabilities and stockholders' equity | $ 3,534,229 | $ 9,268,956 |
Balance Sheets (Parentheticals)
Balance Sheets (Parentheticals) - $ / shares | Dec. 31, 2019 | Dec. 31, 2018 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 19,263,841 | 15,239,148 |
Common stock, shares outstanding (in shares) | 19,263,841 | 15,239,148 |
Statements of Operations
Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Revenues | ||
Cost and expenses: | ||
Depreciation | 13,070 | 5,885 |
Research and development | 1,967,007 | 971,427 |
General and administrative | 8,702,596 | 11,386,229 |
Total costs and expenses | 10,682,673 | 12,363,541 |
Operating loss | (10,682,673) | (12,363,541) |
Interest income | 27,905 | 29,184 |
Interest expense | (37,982) | |
Net loss | $ (10,654,768) | $ (12,372,339) |
Net loss per share — basic and diluted (in dollars per share) | $ (0.66) | $ (0.90) |
Weighted average number of common shares — basic and diluted (in shares) | 16,026,980 | 13,771,020 |
Statements of Changes in Stockh
Statements of Changes in Stockholders' Equity - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2017 | 11,721,584 | |||
Balance at Dec. 31, 2017 | $ 11,721 | $ 17,869,205 | $ (17,452,352) | $ 428,574 |
Issuance of stock for cash (in shares) | 3,282,940 | |||
Issuance of stock for cash | $ 3,284 | 15,386,234 | $ 15,389,518 | |
Issuance of stock for services (in shares) | 234,624 | 200,009 | ||
Issuance of stock for services | $ 235 | 553,068 | $ 553,303 | |
Share based compensation | 4,882,079 | 4,882,079 | ||
Net loss | (12,372,339) | (12,372,339) | ||
Balance (in shares) at Dec. 31, 2018 | 15,239,148 | |||
Balance at Dec. 31, 2018 | $ 15,240 | 38,690,586 | (29,824,691) | 8,881,135 |
Issuance of stock for cash (in shares) | 3,517,986 | |||
Issuance of stock for cash | $ 3,518 | 1,263,676 | $ 1,267,194 | |
Issuance of stock for services (in shares) | 506,707 | 506,707 | ||
Issuance of stock for services | $ 506 | 469,082 | $ 469,588 | |
Share based compensation | 3,060,396 | 3,060,396 | ||
Net loss | (10,654,768) | (10,654,768) | ||
Balance (in shares) at Dec. 31, 2019 | 19,263,841 | |||
Balance at Dec. 31, 2019 | $ 19,264 | $ 43,483,740 | $ (40,479,459) | $ 3,023,545 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Cash flows from operating activities: | ||
Net loss | $ (10,654,768) | $ (12,372,339) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 13,070 | 5,885 |
Share based compensation | 3,529,984 | 5,435,382 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 8,642 | (453) |
Prepaid expenses and other | 65,135 | (213,372) |
Deposits | (3,647) | (18,085) |
Deferred offering costs | 759,591 | |
Accounts payable and accrued expenses | 141,189 | (443,143) |
Other current liabilities | (18,326) | |
Net cash used in operating activities | (6,918,721) | (6,846,534) |
Cash flows from investing activities: | ||
Additions to property and equipment | (33,370) | (22,435) |
Additions to intellectual property | (111,749) | (80,882) |
Additions to research and development supplies | (801,780) | |
Net cash used in investing activities | (946,899) | (103,317) |
Cash flows from financing activities: | ||
Proceeds from issuances of common stock | 1,267,194 | 15,389,518 |
Net cash provided by financing activities | 1,267,194 | 15,389,518 |
Net (decrease) increase in cash | (6,598,426) | 8,439,667 |
Cash, beginning of year | 8,600,918 | 161,251 |
Cash, end of year | $ 2,002,492 | $ 8,600,918 |
Note 1 - Description of Busines
Note 1 - Description of Business and Basis of Presentation | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1 Genprex™ is a clinical stage gene therapy company developing potentially life-changing treatments for cancer and diabetes. Our cancer therapies are based upon our novel proprietary technology platform, including our lead drug candidate, Oncoprex™ immunogene therapy, or Oncoprex, for non-small cell lung cancer (NSCLC). Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an “immunogene therapy”. The gene is one 1 2 Oncology Platform Technologies Our oncology platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. With Oncoprex, we are initially targeting NSCLC. According to the World Health Organization, lung cancer is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver, prostate or skin cancers, and lung cancer is one two million 1.7 In January, 2020, 18 2020 2021. Diabetes Gene Therapy Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves. The most common is type 2 three 2 1 no 422 1.6 Our diabetes gene therapy was developed by lead researcher Dr. George Gittes, at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh. It works by reprogramming beta cells in the pancreas to restore their function, thereby replenishing levels of insulin. The infusion process uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 The diabetes gene therapy has been tested in vivo four Capital Requirements, Liquidity and Going Concern Considerations Our financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying financial statements, we have sustained substantial losses from operations since inception and have no Management recognizes that we must obtain additional resources to successfully commercialize our intellectual property. To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, no not not |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 2 The Company’s financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Accordingly, they do not not not Capital Stock In connection with the Company’s completed IPO in April 2018, 6.6841954 1. 210,000,000 200,000,000 $0.001 10,000,000 $0.001 Use of Estimates The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash We consider all highly liquid short-term investments with an initial maturity of three no $1,761,278 $8,465,768 $250,000 December 31, 2019 December 31, 2018 Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. ASC 820, 820’s 820 Level 1: Quoted prices for identical instruments in active markets. Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not Level 3: Instruments with primarily unobservable value drivers. Property and Equipment Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five Research and Development Materials Costs Research and development expenditures are comprised of costs incurred to conduct research and development activities. These include payments to collaborative research partners, including wages and associated employee benefits, facilities and overhead costs. These expenditures relate to preclinical, Phase I, and Phase II clinical trials and are expensed as incurred. Purchased materials to be used in future research are capitalized and included in research and development supplies. Research and development supplies purchased and capitalized for future use was $801,780 $0 December 31, 2019 December 31, 2018, Awards In 2010, $4.5 two $2.25 2010 2011. In 2010, $244,500 2011 no Intellectual Property Intellectual property consists of external legal and related costs associated with patents and other proprietary technology acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These legal costs incurred in connection with the patent applications and patent maintenance are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. Accounting for Stock-Based Compensation We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date, and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. Financial Instruments We have elected the Fair Value Option to account for the Investment Unit at fair value as a combined hybrid financial instrument containing a Warrant and a Note (see Investment Unit Note). Prior to its exercise, the Warrant component was not not not Due to the contingent terms of the financial instruments, changes in the fair value of the Investment Unit were calculated and realized in earnings. There were no December 31, 2019 August 2019, Long-Lived Assets We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2019 December 31, 2018 no Recent Accounting Developments Accounting pronouncements issued but not December 31, 2019 not |
Note 3 - Intellectual Property
Note 3 - Intellectual Property | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | Note 3 We have exclusive license agreements on thirty-four 34 |
Note 4 - Investment Unit
Note 4 - Investment Unit | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements | |
Investment Unit [Text Block] | Note 4 The Texas Emerging Technology Fund (“TETF”) was created as an incentive for economic development to the Texas economy by providing financial support that leverages private investment for the creation of high-quality technology jobs in Texas. The award received required us to comply with certain performance conditions to ensure the monies the Company received were used for development activities in the state of Texas, and that we maintained our corporate nexus in Texas. Further, in connection with the award, the Company issued an Investment Unit to the TETF. On September 25, 2017 August 16, 2019, Promissory Note The Promissory Note was an obligation to repay the $4.5 8% August 13, 2020. no August 13, 2020, Consistent with the stated objectives of the TETF, an event of default that would trigger the repayment obligation under the Promissory Note was a failure to maintain our principal place of business or our principal executive offices headquartered in the State of Texas (referred to as the “Residency Requirement”) until August 13, 2020. Warrant The Warrant was an obligation to issue (a Right to purchase by the TETF) shares of the same class of stock to be issued in a “First Qualifying Financing Transaction,” at 80% 20% $0.001 The Warrant included a provision that required changes in the strike price, driven by the pricing of the “First Qualifying Financing Transaction.” As a result, the Warrant embedded in the Investment Unit was accounted for as a derivative financial instrument and classified outside of equity under ASC 815 40 15 not On March 12, 2014, $0.001 184,797 1,235,219 Accounting for the Investment Unit We accounted for the Investment Unit as a hybrid financial instrument under FASB Statement 155, December 2013, $2.5 $0.001 March 2014, 184,797 1,235,219 |
Note 5 - Equity
Note 5 - Equity | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 5 Initial Public Offering On April 3, 2018, 1,280,000 $5.00 $5,025,000 $895,000. 3% 38,400 Private Investment On May 9, 2018, 828,500 $12.07 621,376 $15.62 three no $4.25 $9,250,000 On August 1, 2018, 1 No. 333 225090 1,174,440 2,283,740 $4.25 Registered Direct Offering On November 22, 2019, 3,167,986 $0.40 3,167,986 $0.46 first May 22, 2020. $1,093,000 7% 443,518 125% $0.58 In connection with the closing of the Company’s RDO, the Company further adjusted the warrants to purchase up to 2,283,740 May 9, 2018 August 2018 $4.25 $0.46 May 22, 2020, six one Stock Issuances During the year ended December 31, 2019 3,167,986 $1,267,194, 506,707 $469,588, 350,000 During the year ended December 31, 2018 200,009 $553,303, 3,282,940 $16,400,000. Preferred Stock In connection with the Company’s IPO, all Preferred Stock included in Series A through Series G, totaling 1,394,953 December 31, 2018 9,324,177 10,000,000 $0.001 none December 31, 2019 Common Stock Upon the completion of the IPO, all of the Company’s non-voting Common Stock automatically converted into Voting Common Stock on a one one 200,000,000 $0.001 19,263,841 December 31, 2019 Common Stock Purchase Warrants Common Stock purchase warrant activity for the years ended December 31, 2019 2018 Number of Warrants Weighted Avg. Exercise Price Outstanding at January 1, 2018 748,060 $ 5.17 Issued 3,166,492 1.74 Cancelled or expired (15,385 ) — Exercised (34,615 ) — Outstanding at December 31, 2018 3,864,552 $ 2.36 Issued 3,611,504 0.47 Cancelled or expired — — Exercised — — Outstanding at December 31, 2019 7,476,056 $ 1.45 In the year ending December 31, 2019 3,167,986 $0.46 443,518 $0.58 May 2018, 2,283,740 $4.25 $0.46 In the year ended December 31, 2018, 38,400 $6.25 2,283,740 $4.25 844,352 $2,203,506 425,000 225,000 144,352 50,000 $5.00 On January 29, 2018, 6,000 $5.00 $30,000 December 31, 2019, not On September 20, 2018, 50,000 34,615 15,385 2018 The Company’s board of directors and stockholders have approved and adopted the Company’s 2018 “2018 April 3, 2018. 2018 may may A total of 4,160,000 2018 554,963 2009 2018 No 2009 2009 2009 2018 In addition, the number of shares of Common Stock reserved for issuance under the 2018 January 1 January 1, 2019 5% December 31 2018 January 1, 2019 2020, 2018 761,957 963,192 2018 The Company’s board of directors and stockholders have approved and adopted the Company’s 2018 April 3, 2018. 208,500 January 1 January 1, 2019 2% December 31 not January 1, 2019 January 1, 2020 not Stock Options As of December 31, 2019, 5,982,923 twelve 12 forty-eight 48 ten $0.001 $9.80. $0.001 $7.93, Expected term: 10 years Risk-free rate: 1.51% 2.63% Volatility: 75.98% 79.89% Dividend yield: 0% In the year ending December 31, 2019, 1,744,300 $0.30 $1.62 297,058 In the year ended December 31, 2018, 2,034,525 $2.15 $9.80 127,593 The weighted average remaining contractual term for the outstanding options at December 31, 2019 2018 7.45 7.74 Stock option activity for the years ended December 31, 2019 2018 Number of Shares Weighted Avg. Exercise Price Outstanding at January 1, 2018 2,628,749 $ 1.31 Options granted 2,034,525 6.21 Options exercised — — Options expired (127,593 ) — Outstanding at December 31, 2018 4,535,681 $ 3.31 Options granted 1,744,300 1.48 Options exercised — — Options expired (297,058 ) — Outstanding at December 31, 2019 5,982,923 $ 2.66 Share-Based Compensation As of December 31, 2019, not $4.5 two $4.3 $0.2 December 31, 2019, 1.86 0.47 As of December 31, 2019, not $1.3 may 1.35 December 31, 2019. In the year ended December 31, 2019, $3.5 $3.0 |
Note 6 - Related Party Transact
Note 6 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 6 Domecq Sebastian, LLC Domecq-Sebastian LLC (“Domecq”) is an entity affiliated with David Nance, a former director and officer who is now deceased. During December 2017, $200,000 15% March 31, 2018. 18% April 2018. Introgen Research Institute Introgen Research Institute (“IRI”) is a Texas-based technology company, currently affiliated with Rodney Varner, our CEO. In April 2009, August 2012, 2011 Rodney Varner Rodney Varner is the Company’s Chief Executive Officer. On March 28, 2018, $45,000 0% five April 30, 2018, 10% April 2018. Viet Ly Viet Ly manages several investment funds that have provided the Company with investment funds since 2013. March 9, 2018, $25,000 0% June 9, 2018, 10% April 2018. The Company entered into a consulting agreement with Viet Ly on April 19, 2018. $175,000 |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 7 Leases On April 16, 2018, not On April 16, 2018, $2,050 April 30, 2020. Commitments MD Anderson We have entered into a clinical study agreement with the University of Texas MD Anderson Cancer Center in Houston, Texas, to administer a Phase I/II clinical trial, combining FUS1 2018 $2 may In July 2018, two TUSC2 $2 may In 2009, one 1% 21 $20,000 National Institutes of Health Our $191,393 $15,393 2016 fourth 2016 $176,000 December 31, 2016 ( $140,000 $36,000 first 2017, $120,000 $36,000, $20,000, $240,000, $20,000 2018, $36,000 $20,000 second 2017. As a result of our modified agreement with the NIH, we have recognized the exchange of the $120,000 $240,000 $120,000 first 2017. $240,000 $20,000 $280,000 December 31, 2019 Contingencies From time to time we may not During October 2017, three 3 December 1, 2015. |
Note 8 - Income Taxes
Note 8 - Income Taxes | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | Note 8 The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences are as follows: Income tax provision at the federal statutory rate 21 % Effect of operating losses (21 )% 0 % At December 31, 2019 $16.5 not 2029. December 31, 2019 December 31, 2018 |
Note 9 - Subsequent Events
Note 9 - Subsequent Events | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 9 Reserves of 2018 2018 On January 1, 2020, 2018 963,192 March 18, 2020, no 2020 2018 no Regulatory Designation On January 14, 2020, Registered Direct Offerings On January 21, 2020, 961,000 $0.24 $200,000 On January 23, 2020, 7,620,000 $1.05 $7.2 On February 19, 2020, 3 $3,000,000. February 21, 2020, 3 5,000,000 $3.50 $16 Option Grants On January 25, 2020, 40,000 On March 12, 2020, 1,090,000 On March 18, 2020, 35,325 License Agreement On February 11, 2020, 1 2 Director & Officer Appointments On March 12, 2020, On March 18, 2020, three F- 21 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2019 | |
Accounting Policies [Abstract] | |
Stockholders' Equity, Policy [Policy Text Block] | Capital Stock In connection with the Company’s completed IPO in April 2018, 6.6841954 1. 210,000,000 200,000,000 $0.001 10,000,000 $0.001 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash We consider all highly liquid short-term investments with an initial maturity of three no $1,761,278 $8,465,768 $250,000 December 31, 2019 December 31, 2018 |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. ASC 820, 820’s 820 Level 1: Quoted prices for identical instruments in active markets. Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not Level 3: Instruments with primarily unobservable value drivers. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Materials Costs Research and development expenditures are comprised of costs incurred to conduct research and development activities. These include payments to collaborative research partners, including wages and associated employee benefits, facilities and overhead costs. These expenditures relate to preclinical, Phase I, and Phase II clinical trials and are expensed as incurred. Purchased materials to be used in future research are capitalized and included in research and development supplies. Research and development supplies purchased and capitalized for future use was $801,780 $0 December 31, 2019 December 31, 2018, |
Awards [Policy Text Block] | Awards In 2010, $4.5 two $2.25 2010 2011. In 2010, $244,500 2011 no |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Intellectual Property Intellectual property consists of external legal and related costs associated with patents and other proprietary technology acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These legal costs incurred in connection with the patent applications and patent maintenance are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. |
Share-based Payment Arrangement [Policy Text Block] | Accounting for Stock-Based Compensation We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date, and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. |
Financial Instruments Measurement [Policy Text Block] | Financial Instruments We have elected the Fair Value Option to account for the Investment Unit at fair value as a combined hybrid financial instrument containing a Warrant and a Note (see Investment Unit Note). Prior to its exercise, the Warrant component was not not not Due to the contingent terms of the financial instruments, changes in the fair value of the Investment Unit were calculated and realized in earnings. There were no December 31, 2019 August 2019, |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Long-Lived Assets We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2019 December 31, 2018 no |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Developments Accounting pronouncements issued but not December 31, 2019 not |
Note 5 - Equity (Tables)
Note 5 - Equity (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Warrants Weighted Avg. Exercise Price Outstanding at January 1, 2018 748,060 $ 5.17 Issued 3,166,492 1.74 Cancelled or expired (15,385 ) — Exercised (34,615 ) — Outstanding at December 31, 2018 3,864,552 $ 2.36 Issued 3,611,504 0.47 Cancelled or expired — — Exercised — — Outstanding at December 31, 2019 7,476,056 $ 1.45 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Expected term: 10 years Risk-free rate: 1.51% 2.63% Volatility: 75.98% 79.89% Dividend yield: 0% |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Number of Shares Weighted Avg. Exercise Price Outstanding at January 1, 2018 2,628,749 $ 1.31 Options granted 2,034,525 6.21 Options exercised — — Options expired (127,593 ) — Outstanding at December 31, 2018 4,535,681 $ 3.31 Options granted 1,744,300 1.48 Options exercised — — Options expired (297,058 ) — Outstanding at December 31, 2019 5,982,923 $ 2.66 |
Note 8 - Income Taxes (Tables)
Note 8 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Income tax provision at the federal statutory rate 21 % Effect of operating losses (21 )% 0 % |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Details Textual) | Apr. 03, 2018$ / sharesshares | Dec. 31, 2013USD ($) | Dec. 31, 2019USD ($)$ / sharesshares | Dec. 31, 2018USD ($)$ / sharesshares | Dec. 31, 2011USD ($) | Dec. 31, 2010USD ($) | Mar. 31, 2018$ / sharesshares |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 6.6841954 | ||||||
Capital Stock, Shares Authorized | shares | 210,000,000 | ||||||
Common Stock, Shares Authorized | shares | 200,000,000 | 200,000,000 | 200,000,000 | 200,000,000 | |||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||
Preferred Stock, Shares Authorized | shares | 10,000,000 | 10,000,000 | |||||
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.001 | $ 0.001 | |||||
Cash Equivalents, at Carrying Value, Total | $ 0 | ||||||
Cash, Uninsured Amount | 1,761,278 | $ 8,465,768 | |||||
Research and Development Assets, Current | 801,780 | 0 | |||||
State of Texas Emerging Technology Fund Award Amount | $ 4,500,000 | ||||||
Proceeds from State of Texas Emerging Technology Fund Award | $ 2,250,000 | 2,250,000 | |||||
Revenues, Total | |||||||
Fair Value Adjustment of Warrants | $ 2,500,000 | 0 | |||||
Impairment of Long-Lived Assets Held-for-use | $ 0 | $ 0 | |||||
Grant [Member] | U.S. Treasury Department [Member] | |||||||
Revenues, Total | $ 244,500 | ||||||
Minimum [Member] | |||||||
Property, Plant and Equipment, Useful Life | 3 years | ||||||
Maximum [Member] | |||||||
Property, Plant and Equipment, Useful Life | 5 years |
Note 3 - Intellectual Property
Note 3 - Intellectual Property (Details Textual) | Dec. 31, 2019 |
Number of Patents | 34 |
Note 4 - Investment Unit (Detai
Note 4 - Investment Unit (Details Textual) - USD ($) | Apr. 03, 2018 | Mar. 12, 2014 | Dec. 31, 2013 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.45 | $ 2.36 | $ 5.17 | |||
Fair Value Adjustment of Warrants | $ 2,500,000 | $ 0 | ||||
Conversion of Preferred Stock to Common Stock [Member] | ||||||
Conversion of Stock, Shares Issued | 1,235,219 | 9,324,177 | ||||
Series B Preferred Stock [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 184,797 | |||||
Warrant Issued to TETF [Member] | ||||||
Class of Warrant or Right, Purchase Percentage | 80.00% | |||||
Warrant Discount Rate | 20.00% | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.001 | $ 0.001 | ||||
Promissory Note [Member] | ||||||
Contingent Debt | $ 4,500,000 | |||||
Contingent Debt, Interest Rate | 8.00% |
Note 5 - Equity (Details Textua
Note 5 - Equity (Details Textual) | Jan. 25, 2020shares | Jan. 01, 2020shares | Nov. 22, 2019USD ($)$ / sharesshares | Jan. 01, 2019shares | Sep. 20, 2018shares | Aug. 01, 2018$ / sharesshares | May 09, 2018USD ($)$ / sharesshares | Apr. 03, 2018USD ($)$ / sharesshares | Dec. 31, 2019USD ($)$ / sharesshares | Dec. 31, 2018USD ($)$ / sharesshares | Mar. 31, 2018$ / sharesshares | Jan. 29, 2018USD ($)$ / sharesshares | Dec. 31, 2017$ / sharesshares |
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1.45 | $ 2.36 | $ 5.17 | ||||||||||
Proceeds from Issuance of Common Stock | $ | $ 1,267,194 | $ 15,389,518 | |||||||||||
Stock Issued During Period, Shares, Issued for Services | 506,707 | 200,009 | |||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 469,588 | $ 553,303 | |||||||||||
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | |||||||||||
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.001 | $ 0.001 | |||||||||||
Preferred Stock, Shares Outstanding, Ending Balance | 0 | ||||||||||||
Non-voting To Voting Common Stock, Conversion Ratio | 1 | ||||||||||||
Common Stock, Shares Authorized | 200,000,000 | 200,000,000 | 200,000,000 | 200,000,000 | |||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||
Common Stock, Shares, Outstanding, Ending Balance | 19,263,841 | 15,239,148 | |||||||||||
Class of Warrant or Right, Issued in Period | 3,611,504 | 3,166,492 | |||||||||||
Class of Warrant or Right, Issued During Period, Exercise Price | $ / shares | $ 0.47 | $ 1.74 | |||||||||||
Class of Warrant or Right, Exercised During Period | 34,615 | ||||||||||||
Class of Warrant or Right, Cancelled During Period | 15,385 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 5,982,923 | 4,535,681 | 2,628,749 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares | $ 2.66 | $ 3.31 | $ 1.31 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,744,300 | 2,034,525 | |||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 1.48 | $ 6.21 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total | 297,058 | 127,593 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 7 years 164 days | 7 years 270 days | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ | $ 4.50 | ||||||||||||
Share-based Payment Arrangement, Expense | $ | 3,500,000 | ||||||||||||
Graded Vesting Method [Member] | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ | 4,300,000 | ||||||||||||
Cliff Vesting Method [Member] | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ | $ 200,000 | ||||||||||||
Share-based Payment Arrangement, Option [Member] | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 2 years | ||||||||||||
Share-based Payment Arrangement, Expense | $ | $ 3,000,000 | ||||||||||||
Performance Shares [Member] | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 1 year 127 days | ||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ | $ 1.30 | ||||||||||||
Subsequent Event [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 40,000 | ||||||||||||
The 2018 Equity Incentive Plan [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 4,160,000 | ||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year | 5.00% | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 761,957 | ||||||||||||
The 2018 Equity Incentive Plan [Member] | Subsequent Event [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 963,192 | ||||||||||||
The 2009 Plan [Member] | |||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance | 554,963 | ||||||||||||
The 2018 Employee Stock Purchase Plan [Member] | |||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year | 2.00% | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 208,500 | ||||||||||||
Conversion of Preferred Stock to Common Stock [Member] | |||||||||||||
Conversion of Stock, Shares Converted | 1,394,953 | ||||||||||||
Conversion of Stock, Shares Issued | 1,235,219 | 9,324,177 | |||||||||||
World Wide Holdings, LLC [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 50,000 | ||||||||||||
Class of Warrant or Right, Exercised During Period | 34,615 | ||||||||||||
Class of Warrant or Right, Cancelled During Period | 15,385 | ||||||||||||
Warrants Issued with Registered Direct Offering [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 3,167,986 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.46 | ||||||||||||
Warrants Issued to Underwriter [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 443,518 | 3,167,986 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.58 | $ 0.46 | |||||||||||
Warrants, Exercise Price, Percentage of RDO Price Per Share | $ / shares | $ 125 | ||||||||||||
Class of Warrant or Right, Issued in Period | 38,400 | ||||||||||||
Class of Warrant or Right, Issued During Period, Exercise Price | $ / shares | $ 6.25 | ||||||||||||
Warrants Issued to Investors to Purchase Common Stock [Member] | |||||||||||||
Class of Warrant or Right, Issued in Period | 2,283,740 | ||||||||||||
Class of Warrant or Right, Issued During Period, Exercise Price | $ / shares | $ 4.25 | ||||||||||||
Warrants Issued for Services [Member] | |||||||||||||
Class of Warrant or Right, Issued in Period | 844,352 | ||||||||||||
Warrants and Rights Outstanding | $ | $ 2,203,506 | ||||||||||||
Warrants Issued for Services [Member] | Cancer Revolution, LLC [Member] | |||||||||||||
Class of Warrant or Right, Issued in Period | 425,000 | ||||||||||||
Warrants Issued for Services [Member] | Cancer Biotech, LLC [Member] | |||||||||||||
Class of Warrant or Right, Issued in Period | 225,000 | ||||||||||||
Warrants Issued for Services [Member] | Inception Capital Management, LLC [Member] | |||||||||||||
Class of Warrant or Right, Issued in Period | 144,352 | ||||||||||||
Warrants Issued for Services [Member] | World Wide Holdings, LLC [Member] | |||||||||||||
Class of Warrant or Right, Issued in Period | 50,000 | ||||||||||||
Class of Warrant or Right, Issued During Period, Exercise Price | $ / shares | $ 5 | ||||||||||||
Warrants Issued for Services [Member] | FundAthena, Inc [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 6,000 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 5 | ||||||||||||
Class of Warrant or Right, Issued in Period | 0 | ||||||||||||
Accounts Payable, Total | $ | $ 30,000 | ||||||||||||
Maximum [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares | $ 9.80 | $ 9.80 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | $ / shares | 7.93 | ||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 1.62 | ||||||||||||
Minimum [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 1 year | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares | $ 0.001 | $ 2.15 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | $ / shares | 0.001 | ||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 0.30 | ||||||||||||
Weighted Average [Member] | Share-based Payment Arrangement, Option [Member] | Graded Vesting Method [Member] | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 1 year 313 days | ||||||||||||
Weighted Average [Member] | Share-based Payment Arrangement, Option [Member] | Cliff Vesting Method [Member] | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 171 days | ||||||||||||
IPO [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 1,280,000 | ||||||||||||
Sale of Stock, Price Per Share | $ / shares | $ 5 | ||||||||||||
Proceeds from Issuance Initial Public Offering | $ | $ 5,025,000 | ||||||||||||
Payments of Stock Issuance Costs | $ | $ 895,000 | ||||||||||||
Percentage of Common Stock Issuance of Warrant or Right Issued | 3.00% | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 38,400 | ||||||||||||
Private Placement [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 828,500 | 350,000 | |||||||||||
Sale of Stock, Price Per Share | $ / shares | $ 12.07 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 15.62 | ||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 9,250,000 | ||||||||||||
Private Placement [Member] | Securities Purchase Agreement [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 1,174,440 | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 2,283,740 | 2,283,740 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 4.25 | $ 0.46 | |||||||||||
Private Placement [Member] | Maximum [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 621,376 | ||||||||||||
Private Placement [Member] | Minimum [Member] | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 4.25 | ||||||||||||
Registered Direct Offering [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 3,167,986 | 3,167,986 | |||||||||||
Proceeds from Issuance of Common Stock | $ | $ 1,093,000 | $ 1,267,194 | |||||||||||
Shares Issued, Price Per Share | $ / shares | $ 0.40 | ||||||||||||
Registered Direct Offering [Member] | Underwriter [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 443,518 | ||||||||||||
Percentage of Common Stock Issuance of Warrant or Right Issued | 7.00% | ||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 0.58 | ||||||||||||
IPO and Private Placement [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 3,282,940 | ||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 16,400,000 |
Note 5 - Equity - Common Stock
Note 5 - Equity - Common Stock Purchase Warrant Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Outstanding, number of warrants (in shares) | 3,864,552 | 748,060 |
Outstanding, weighted average exercise price (in dollars per share) | $ 2.36 | $ 5.17 |
Issued, number of warrants (in shares) | 3,611,504 | 3,166,492 |
Issued, weighted average exercise price (in dollars per share) | $ 0.47 | $ 1.74 |
Cancelled or expired, number of warrants (in shares) | (15,385) | |
Cancelled or expired, weighted average exercise price (in dollars per share) | ||
Exercised, number of warrants (in shares) | (34,615) | |
Exercised, weighted average exercise price (in dollars per share) | ||
Outstanding, number of warrants (in shares) | 7,476,056 | 3,864,552 |
Outstanding, weighted average exercise price (in dollars per share) | $ 1.45 | $ 2.36 |
Note 5 - Equity - Assumptions (
Note 5 - Equity - Assumptions (Details) | 12 Months Ended |
Dec. 31, 2019 | |
Expected term: (Year) | 10 years |
Dividend yield: | 0.00% |
Minimum [Member] | |
Risk-free rate: | 1.51% |
Volatility: | 75.98% |
Maximum [Member] | |
Risk-free rate: | 2.63% |
Volatility: | 79.89% |
Note 5 - Equity - Stock Option
Note 5 - Equity - Stock Option Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Outstanding, number of shares (in shares) | 4,535,681 | 2,628,749 |
Outstanding, weighted average exercise price (in dollars per share) | $ 3.31 | $ 1.31 |
Options granted, number of shares (in shares) | 1,744,300 | 2,034,525 |
Options granted, weighted average exercise price (in dollars per share) | $ 1.48 | $ 6.21 |
Options exercised, number of shares (in shares) | ||
Options expired, number of shares (in shares) | (297,058) | (127,593) |
Outstanding, number of shares (in shares) | 5,982,923 | 4,535,681 |
Outstanding, weighted average exercise price (in dollars per share) | $ 2.66 | $ 3.31 |
Note 6 - Related Party Transa_2
Note 6 - Related Party Transactions (Details Textual) - USD ($) | Apr. 19, 2018 | Mar. 28, 2018 | Mar. 09, 2018 | Dec. 31, 2017 |
Domecq Sebastion, LLC [Member] | Promissory Note [Member] | ||||
Debt Instrument, Face Amount | $ 200,000 | |||
Debt Instrument, Interest Rate, Stated Percentage | 15.00% | |||
Debt Instrument, Interest Rate, Stated Percentage After Maturity Date | 18.00% | |||
Chief Executive Officer [Member] | Promissory Note [Member] | ||||
Debt Instrument, Face Amount | $ 45,000 | |||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | |||
Debt Instrument, Interest Rate, Stated Percentage After Maturity Date | 10.00% | |||
Viet Ly [Member] | ||||
Related Party, Initial Annual Consulting Compensation to be Paid | $ 175,000 | |||
Viet Ly [Member] | Promissory Note [Member] | ||||
Debt Instrument, Face Amount | $ 25,000 | |||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | |||
Debt Instrument, Interest Rate, Stated Percentage After Maturity Date | 10.00% |
Note 7 - Commitments and Cont_2
Note 7 - Commitments and Contingencies (Details Textual) - USD ($) | Apr. 16, 2018 | Jul. 31, 2018 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2016 | Dec. 31, 2009 | Oct. 31, 2017 |
Operating Lease, Rent Expense Per Month | $ 2,050 | |||||||||
Payments to Acquire Intangible Assets | $ 111,749 | $ 80,882 | ||||||||
Percentage of Outstanding Shares for Warrant to Purchase Shares of Common Stock | 3.00% | |||||||||
National Institute of Health [Member] | ||||||||||
Royalty on Sales, Percentage | 1.00% | |||||||||
Royalty Term | 21 years | |||||||||
Royalty Payment, Annual Minimum | $ 20,000 | |||||||||
Other Commitment, Total | $ 191,393 | $ 280,000 | $ 191,393 | |||||||
Legal Fees | 15,393 | |||||||||
Accounts Payable, Other, Current | 176,000 | 176,000 | ||||||||
Accrued Royalties, Current | $ 140,000 | 140,000 | ||||||||
Other Expenses, Total | $ 36,000 | |||||||||
Extinguishment of Debt, Amount | $ 120,000 | |||||||||
Accrued Patent Costs, Current | 36,000 | |||||||||
Payments for Royalties | $ 20,000 | 20,000 | ||||||||
Payment for Contingent Consideration Liability, Operating Activities | 240,000 | |||||||||
Contingent Payments Annual Increase | 20,000 | |||||||||
Payments to Acquire Intangible Assets | $ 36,000 | |||||||||
Finite-Lived Intangible Assets, Period Increase (Decrease), Total | $ (120,000) | |||||||||
Clinical Trial Agreement [Member] | MD Anderson [Member] | ||||||||||
Long Term Contract, Estimated Cost | $ 2,000,000 | |||||||||
Research Agreement [Member] | MD Anderson [Member] | ||||||||||
Long Term Contract, Estimated Cost | $ 2,000,000 |
Note 8 - Income Taxes (Details
Note 8 - Income Taxes (Details Textual) $ in Millions | Dec. 31, 2019USD ($) |
Operating Loss Carryforwards, Total | $ 16.5 |
Note 8 - Income Taxes - Income
Note 8 - Income Taxes - Income Tax Reconciliation (Details) | 12 Months Ended |
Dec. 31, 2019 | |
Income tax provision at the federal statutory rate | 21.00% |
Effect of operating losses | (21.00%) |
0.00% |
Note 9 - Subsequent Events (Det
Note 9 - Subsequent Events (Details Textual) - USD ($) | Mar. 18, 2020 | Mar. 12, 2020 | Feb. 21, 2020 | Feb. 19, 2020 | Jan. 25, 2020 | Jan. 23, 2020 | Jan. 21, 2020 | Jan. 01, 2020 | Nov. 22, 2019 | Jan. 01, 2019 | Dec. 31, 2019 | Dec. 31, 2018 |
Proceeds from Issuance of Common Stock | $ 1,267,194 | $ 15,389,518 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,744,300 | 2,034,525 | ||||||||||
Registered Direct Offering [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues | 3,167,986 | 3,167,986 | ||||||||||
Shares Issued, Price Per Share | $ 0.40 | |||||||||||
Proceeds from Issuance of Common Stock | $ 1,093,000 | $ 1,267,194 | ||||||||||
Subsequent Event [Member] | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 40,000 | |||||||||||
Subsequent Event [Member] | Officer [Member] | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,090,000 | |||||||||||
Subsequent Event [Member] | Director [Member] | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 35,325 | |||||||||||
Subsequent Event [Member] | Registered Direct Offering [Member] | ||||||||||||
Registered Direct Offerings, Maximum Offering Size, Increase | $ 3,000,000 | |||||||||||
Subsequent Event [Member] | Registered Direct Offering [Member] | Accredited Investor [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues | 961,000 | |||||||||||
Shares Issued, Price Per Share | $ 0.24 | |||||||||||
Proceeds from Issuance of Common Stock | $ 200,000 | |||||||||||
Subsequent Event [Member] | Registered Direct Offering [Member] | Investors [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues | 5,000,000 | 7,620,000 | ||||||||||
Shares Issued, Price Per Share | $ 3.50 | $ 1.05 | ||||||||||
Proceeds from Issuance of Common Stock | $ 16,000,000 | $ 7.20 | ||||||||||
The 2018 Equity Incentive Plan [Member] | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 761,957 | |||||||||||
The 2018 Equity Incentive Plan [Member] | Subsequent Event [Member] | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 963,192 |